Johnson & Johnson $JNJ Shares Sold by Iowa State Bank

Iowa State Bank reduced its position in shares of Johnson & Johnson (NYSE:JNJ) by 6.5% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 31,226 shares of the company’s stock after selling 2,168 shares during the period. Johnson & Johnson comprises approximately 1.3% of Iowa State Bank’s holdings, making the stock its 24th largest holding. Iowa State Bank’s holdings in Johnson & Johnson were worth $8,267,000 at the end of the most recent quarter.

Several other large investors have also recently added to or reduced their stakes in the company. Outlook Capital Management LLC acquired a new stake in shares of Johnson & Johnson during the second quarter worth $28,000. Matrix Trust Co boosted its holdings in shares of Johnson & Johnson by 56.2% in the 2nd quarter. Matrix Trust Co now owns 150 shares of the company’s stock valued at $38,000 after buying an additional 54 shares during the period. Montgomery Financial Services LLC bought a new stake in shares of Johnson & Johnson during the 2nd quarter valued at about $43,000. Hyposwiss Advisors SA acquired a new stake in Johnson & Johnson during the fourth quarter worth about $42,000. Finally, Polaris Financial Partners bought a new position in Johnson & Johnson in the third quarter worth about $56,000. 69.55% of the stock is currently owned by institutional investors.

Johnson & Johnson Stock Performance

Johnson & Johnson stock traded up $1.52 during mid-day trading on Tuesday, hitting $254.45. 2,366,547 shares of the company’s stock traded hands, compared to its average volume of 7,977,621. The company has a quick ratio of 0.81, a current ratio of 1.09 and a debt-to-equity ratio of 0.44. Johnson & Johnson has a one year low of $182.94 and a one year high of $281.07. The firm has a 50 day moving average price of $266.10 and a 200 day moving average price of $248.51. The company has a market cap of $613.19 billion, a PE ratio of 29.48, a price-to-earnings-growth ratio of 2.52 and a beta of 0.21.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Wednesday, July 15th. The company reported $2.90 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.84 by $0.06. Johnson & Johnson had a return on equity of 32.42% and a net margin of 21.48%.The company had revenue of $25.31 billion during the quarter, compared to analysts’ expectations of $25.06 billion. During the same quarter in the prior year, the business posted $2.77 earnings per share. The company’s revenue for the quarter was up 6.6% compared to the same quarter last year. Johnson & Johnson has set its FY 2026 guidance at 11.600-11.750 EPS. On average, equities analysts forecast that Johnson & Johnson will post 11.54 EPS for the current year.

Johnson & Johnson Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Tuesday, September 8th. Shareholders of record on Tuesday, August 25th were paid a dividend of $1.34 per share. The ex-dividend date of this dividend was Tuesday, August 25th. This represents a $5.36 annualized dividend and a yield of 2.1%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 62.11%.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on the company. Morgan Stanley upped their target price on Johnson & Johnson from $284.00 to $294.00 and gave the company an “overweight” rating in a report on Thursday, July 16th. Royal Bank Of Canada boosted their price objective on Johnson & Johnson from $287.00 to $290.00 and gave the company an “outperform” rating in a research report on Tuesday. Guggenheim upped their price objective on Johnson & Johnson from $270.00 to $287.00 and gave the stock a “buy” rating in a research note on Thursday, August 6th. Wells Fargo & Company raised their target price on Johnson & Johnson from $272.00 to $282.00 and gave the company an “overweight” rating in a research note on Monday, August 3rd. Finally, Argus set a $300.00 price target on shares of Johnson & Johnson in a research report on Wednesday, July 29th. One analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating and six have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $276.22.

Johnson & Johnson News Summary

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Johnson & Johnson’s diversified pharmaceutical, medical-device and consumer-health businesses, along with new drug launches and sales growth, give it an advantage over Pfizer despite Pfizer’s lower valuation and higher dividend yield. Pfizer vs. J&J: Comparing Growth, Patent Risks and Valuation
• Positive Sentiment: Analysts and financial commentators continue to view J&J as a defensive dividend holding: demand for healthcare products may remain resilient during an economic downturn, supporting its long record of dividend increases. Looking for a Dividend Stock That Can Weather a Downturn?
• Neutral Sentiment: J&J and Procter & Gamble trade at similar valuations, with the investment comparison centered on which company can sustain dividend growth over the next two decades. The discussion supports J&J’s income-investment appeal but does not introduce a new company-specific catalyst. Johnson & Johnson or Procter & Gamble
• Neutral Sentiment: Johnson & Johnson is expected to report earnings on October 13. Although earnings are projected to grow, one analysis says the company lacks the usual combination of estimate revisions and other factors associated with a likely earnings beat, potentially limiting pre-earnings optimism. Johnson & Johnson Earnings Expected to Grow
• Negative Sentiment: Investors remain concerned that a roughly $4 billion revenue patent cliff in 2027 could pressure growth. The key issue is whether J&J’s replacement pipeline and new launches can offset the loss of exclusivity, making the upcoming earnings report more important than the quarterly EPS result alone. Why a $4 Billion 2027 Patent Cliff Matters

Insider Activity at Johnson & Johnson

In related news, EVP Vanessa Broadhurst sold 23,054 shares of the business’s stock in a transaction that occurred on Monday, July 20th. The stock was sold at an average price of $251.27, for a total transaction of $5,792,778.58. Following the sale, the executive vice president owned 23,003 shares of the company’s stock, valued at $5,779,963.81. The trade was a 50.06% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Elizabeth Forminard sold 15,918 shares of the stock in a transaction on Thursday, August 6th. The shares were sold at an average price of $257.00, for a total value of $4,090,926.00. Following the transaction, the executive vice president directly owned 16,994 shares of the company’s stock, valued at approximately $4,367,458. The trade was a 48.37% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 87,569 shares of company stock valued at $23,064,544. 0.16% of the stock is currently owned by insiders.

About Johnson & Johnson

Johnson & Johnson (NYSE: JNJ) is a global healthcare company that develops, manufactures and markets products through two primary business segments: Innovative Medicine and MedTech. Its operations serve patients, healthcare professionals and consumers in markets around the world.

The Innovative Medicine segment focuses on prescription medicines in areas including immunology, oncology, neuroscience, cardiovascular and metabolic disease, infectious diseases, and pulmonary hypertension.